Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TyRx, a medical device manufacturer, has launched its Aigisrx ICD, an anti-bacterial envelope developed to help stabilize the implanted device and which also contains anti-microbial agents that help provide protection against surgical site infections associated with implantable cardioverter defibrillators.
Subscribe to our email newsletter
The launch of Aigisrx implantable cardioverter defibrillator (ICD) is said to extend TyRx’s Aigisrx cardiac rhythm management device (CRMD) platform to the implantable cardioverter defibrillator market.
The Aigisrx CRMD platform also includes Aigisrx PM, the company’s anti-bacterial coated mesh designed specifically for implanted pacemakers.
Bill Edelman, CEO of TyRx, said: “The launch of Aigisrx ICD offers a unique and potentially groundbreaking solution for protecting an extremely vulnerable patient population, while allowing hospitals to reduce the incidence and cost of treating surgical site infections related to ICD implantation.”